Menu
en
fr
nl
A propos
Bone Therapeutics en bref
Mission
Equipe de direction
Conseil d’administration
Comité consultatif scientifique
Équipe
Technologie
Plateforme technologique unique
Propriété intellectuelle
Produits
Portefeuille
ALLOB
JTA-004
Indications
Études cliniques
Généralités
Études en cours
Interviews d'investigateurs
Participation
Partenariats
Nos partenaires
Possibilité d'octroi de licences
Investisseurs
Prix de l’action
Espace actionnaires
Calendrier financier
Informations financières
Informations réglementées
Gouvernance d'entreprise
Assemblée générale
Présentations
Evènements
Relations Investisseurs
Carrières
Offres d'emploi
Candidatures spontanées
Témoignages
Actualités & événements
Communiqués de presse
Couverture Médiatique
Actualités
Événements à venir
Inscription aux actualités
10 ans
Contact
Contact
si vous êtes un robot, tapez quelque chose
Home
Actualités & événements
Communiqués de presse
Communiqués de presse
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
mars
30/03/2021 - Bone Therapeutics appoints industry cell therapy expert, Anthony Ting, PhD as Chief Scientific Officer
17/03/2021 - Bone Therapeutics to present in M Vest LLC and Maxim Group LLC Emerging Growth Virtual Conference
février
09/02/2021 - Bone Therapeutics: Notice of Extraordinary Shareholders’ Meeting on 26 February 2021
janvier
20/01/2021 - Bone Therapeutics provides fourth quarter 2020 business update and 2021 outlook
14/01/2021 - Bone Therapeutics and Rigenerand sign partnership for cell therapy process development
12/01/2021 - Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study
08/01/2021 - Bone Therapeutics: Notice of Extraordinary Shareholders’ Meeting on 8 February 2021
décembre
24/12/2020 - Transparency notification received from CPH Banque
24/12/2020 - Bone Therapeutics: Information on the total number of voting rights and shares (December 2020)
22/12/2020 - Bone Therapeutics completes recruitment and patient treatment in JTA-004 pivotal Phase III knee osteoarthritis study
16/12/2020 - Bone Therapeutics announces closing of private placement
11/12/2020 - Bone Therapeutics announces pricing of private placement
novembre
16/11/2020 - Bone Therapeutics announces completion of the acquisition of its cell therapy manufacturing subsidiary SCTS by Catalent
10/11/2020 - Bone Therapeutics, Cerhum, 3D-Side, mSKIL and IREC awarded €3M in BioWin supported funding to develop personalized, tissue engineered bone implants
octobre
30/10/2020 - Bone Therapeutics Provides Third Quarter 2020 Business Update
29/10/2020 - Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB
23/10/2020 - Transparency notification received from S.R.I.W. SA and Sofipôle SA
23/10/2020 - Bone Therapeutics: Information on the total number of voting rights and shares (October 2020)
20/10/2020 - Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study
14/10/2020 - Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
12/10/2020 - Bone Therapeutics to present at 2020 Virtual Cell & Gene Meeting on the Mesa
05/10/2020 - Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia
septembre
09/09/2020 - Information on the total number of voting rights and shares
août
26/08/2020 - Bone Therapeutics reports half year 2020 results
20/08/2020 - Bone Therapeutics announces expansion of its pipeline supported by funding from the Walloon Region
13/08/2020 - Bone Therapeutics receives EUR 1.0 million to advance ongoing JTA-004 phase III knee osteoarthritis study
juin
11/06/2020 - Bone Therapeutics announces Annual General Meeting results and confirms outlook for 2020
mai
29/05/2020 - Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA
29/05/2020 - Bone Therapeutics: Information on the total number of voting rights and shares (May 2020)
18/05/2020 - Bone Therapeutics treats first patients in pivotal JTA-004 phase III knee osteoarthritis study
11/05/2020 - Bone Therapeutics to host Annual Ordinary General Meeting on 10 June 2020
07/05/2020 - Bone Therapeutics raises additional EUR 4.0 million, with total of EUR 15 million committed, providing runway into Q2 2021
06/05/2020 - Bone Therapeutics Provides First Quarter 2020 Business Update
avril
29/04/2020 - Bone Therapeutics secures EUR 11.0 million financing
03/04/2020 - Bone Therapeutics: Information on the total number of voting rights and shares (March 2020)
mars
26/03/2020 - Bone Therapeutics appoints Stefanos Theoharis as Chief Business Officer
23/03/2020 - Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates
11/03/2020 - Bone Therapeutics announces 2019 full year results
février
28/02/2020 - Bone Therapeutics: Information on the total number of voting rights and shares (February 2020)
11/02/2020 - Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at the Annual Meeting of the ORS
janvier
31/01/2020 - Bone Therapeutics: Information on the total number of voting rights and shares (January 2020)
22/01/2020 - Bone Therapeutics announces 2020 business outlook and reports year-end 2019 cash position
09/01/2020 - Bone Therapeutics announces attendance at the 38th Annual J.P. Morgan Healthcare Conference
décembre
30/12/2019 - Bone Therapeutics: Information on the total number of voting rights and shares (December 2019)
20/12/2019 - Bone Therapeutics advances JTA-004 into pivotal Phase III study
19/12/2019 - Bone Therapeutics announces the appointment of Dr. Miguel Forte as CEO to lead the Company into the next phase of development
09/12/2019 - Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA
novembre
29/11/2019 - Bone Therapeutics: Information on the total number of voting rights and shares (November 2019)
25/11/2019 - Bone Therapeutics: The preliminary documents for the Extraordinary General Shareholder Meeting on 12 December 2019 have been made available
06/11/2019 - Bone Therapeutics Reports Financial Results for the First Nine Months of 2019 and Provides Third Quarter 2019 Business Update
octobre
22/10/2019 - Bone Therapeutics: The preliminary documents for the Extraordinary General Shareholder Meeting on 22 November 2019 have been made available
03/10/2019 - Bone Therapeutics: Information on the total number of voting rights and shares (September 2019)
septembre
27/09/2019 - Bone Therapeutics to present data from its Phase II/III trial with JTA-004 at the 2nd World Congress on Rheumatology & Orthopedics
09/09/2019 - Bone Therapeutics: Information on the total number of voting rights and shares (August 2019)
août
30/08/2019 - Bone Therapeutics reports half year 2019 results
28/08/2019 - Bone Therapeutics to report half year 2019 results on 30 August 2019
juillet
30/07/2019 - Bone Therapeutics: Information on the total number of voting rights and shares (July 2019)
11/07/2019 - Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA
04/07/2019 - Bone Therapeutics: Transparency notification received from Mr. J. Reymann
02/07/2019 - Bone Therapeutics: Information on the total number of voting rights and shares
juin
27/06/2019 - Bone Therapeutics successfully raises EUR 8.5 million
27/06/2019 - Bone Therapeutics to raise capital through private placement of new shares and issuance of non-dilutive subordinated bonds
21/06/2019 - Bone Therapeutics: Information on the total number of voting rights and shares (June 2019)
13/06/2019 - Bone Therapeutics’ allogeneic cell therapy product ALLOB meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion
13/06/2019 - Bone Therapeutics’ allogeneic cell therapy product ALLOB meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion
12/06/2019 - Bone Therapeutics announces results of Annual General Meeting
mai
31/05/2019 - Bone Therapeutics to participate in upcoming conferences
29/05/2019 - Bone Therapeutics: Information on the total number of voting rights and shares (May 2019)
24/05/2019 - Bone Therapeutics to present data at TERMIS European Chapter Meeting 2019
24/05/2019 - The preliminary documents for the Extraordinary General Shareholder Meeting on 12 June 2019 have been made available
10/05/2019 - The preliminary documents for the Annual Ordinary General Shareholder Meeting on 12 June 2019 have been made available
07/05/2019 - Bone Therapeutics Provides First Quarter 2019 Business Update
avril
29/04/2019 - Bone Therapeutics: Information on the total number of voting rights and shares (April 2019)
25/04/2019 - Bone Therapeutics announces publication of Annual Report 2018 and Extraordinary General Meeting on 23 May 2019
23/04/2019 - The preliminary documents for the Extraordinary General Shareholder Meeting on 23 May 2019 have been made available
mars
28/03/2019 - Bone Therapeutics: Information on the total number of voting rights and shares (March 2019)
18/03/2019 - Bone Therapeutics to present at Herbert Fleisch / IFMRS Workshop
12/03/2019 - Bone Therapeutics appoints Olivier Godeaux as Chief Medical Officer and Benoit Moreaux as Chief Scientific and Technology Officer
05/03/2019 - Bone Therapeutics: Information on the total number of voting rights and shares (February 2019)
01/03/2019 - Bone Therapeutics announces 2018 full year results
février
25/02/2019 - Bone Therapeutics Notice of Full Year 2018 Results
05/02/2019 - Bone Therapeutics to present at the Annual Meeting of the Orthopaedic Research Society (ORS)
janvier
30/01/2019 - Bone Therapeutics: Information on the total number of voting rights and shares (January 2019)
30/01/2019 - Bone Therapeutics holds successful event to highlight strength of cell and gene therapy in Wallonia
22/01/2019 - Bone Therapeutics announces 2019 business outlook and reports year-end 2018 cash position
décembre
24/12/2018 - Bone Therapeutics: Information on the total number of voting rights and shares (December 2018)
11/12/2018 - Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA
novembre
29/11/2018 - Bone Therapeutics: Information on the total number of voting rights and shares (November 2018)
07/11/2018 - Bone Therapeutics Business Update for Third Quarter 2018
06/11/2018 - Bone Therapeutics announces conclusions from interim analysis of Phase III PREOB study in hip osteonecrosis
octobre
29/10/2018 - Bone Therapeutics announces appointment of Linda Lebon as Chief Regulatory Officer
25/10/2018 - Bone Therapeutics: Information on the total number of voting rights and shares (October 2018)
17/10/2018 - Single intra-articular injection of viscosupplement JTA-004 delivered higher pain reduction than the reference in first study in knee osteoarthritis
septembre
27/09/2018 - Bone Therapeutics: Information on the total number of voting rights and shares (2018-09)
24/09/2018 - Bone Therapeutics to present at 26th Annual Meeting of the European Orthopaedic Research Society
14/09/2018 - Bone Therapeutics announces final results from Phase I/IIA ALLOB delayed-union fracture study
03/09/2018 - Bone Therapeutics: Information on the total number of voting rights and shares
août
30/08/2018 - Bone Therapeutics Announces H1 Results for 2018
08/08/2018 - Bone Therapeutics Notice of Half Year 2018 Results
juillet
20/07/2018 - Bone Therapeutics: Information on the total number of voting rights and shares
juin
21/06/2018 - The preliminary documents for the Extraordinary General Shareholder Meeting on 9 July 2018 have been made available
14/06/2018 - Bone Therapeutics announces results of Annual General Meeting
11/06/2018 - Bone Therapeutics: Information on the total number of voting rights and shares
mai
28/05/2018 - Bone Therapeutics: Information on the total number of voting rights and shares
09/05/2018 - The preliminary documents for the Annual Ordinary and the Extraordinary General Shareholder Meeting on 13 June 2018 have been made available
04/05/2018 - Bone Therapeutics Business Update for First Quarter 2018
04/05/2018 - Bone Therapeutics: Information on the total number of voting rights and shares
avril
26/04/2018 - Bone Therapeutics Strengthens Board with the Appointment of Claudia D'Augusta as Non-Executive Director
25/04/2018 - Bone Therapeutics Reports Full Year 2017 Results
04/04/2018 - Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA
mars
21/03/2018 - Bone Therapeutics: Information on the total number of voting rights and shares
07/03/2018 - Bone Therapeutics Successfully Raises EUR 19.45 Million of Commitments in Convertible Bond Placement
07/03/2018 - Bone Therapeutics Announces Private Placement of Convertible Bonds
février
20/02/2018 - Bone Therapeutics strengthens Board with the appointment of Jean Stéphenne as Chairman
19/02/2018 - Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB
janvier
23/01/2018 - Bone Therapeutics provides business outlook and announces its financial calendar for 2018
19/01/2018 - Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2018
décembre
15/12/2017 - Bone Therapeutics Provides Update on Equity Placement
14/12/2017 - Bone Therapeutics Launches Equity Placement
11/12/2017 - Bone Therapeutics and Cellthera Pharm LLC announce intention to collaborate and Bone Therapeutics provides overview of its pipeline
novembre
09/11/2017 - Bone Therapeutics Business Update for Third Quarter 2017
octobre
24/10/2017 - Bone Therapeutics to participate in upcoming key investor and partnering conferences in Q4 2017
13/10/2017 - The preliminary documents for the Extraordinary General Shareholder Meeting on 30 October 2017 have been made available
septembre
22/09/2017 - Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB in Japan
20/09/2017 - Bone Therapeutics announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis
14/09/2017 - Bone Therapeutics reports strong interim results from ALLOB Phase IIA spinal fusion study
04/09/2017 - The preliminary documents for the Extraordinary General Shareholder Meeting on 5 October 2017 have been made available
août
31/08/2017 - Bone Therapeutics announces H1 results for 2017
31/08/2017 - Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer
24/08/2017 - Bone Therapeutics Notice of Half Year 2017 Results
juillet
03/07/2017 - Bone Therapeutics strengthens board of directors
juin
26/06/2017 - Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform
08/06/2017 - Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB
mai
29/05/2017 - Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive Directors
11/05/2017 - Bone Therapeutics Business Update for First Quarter 2017
avril
26/04/2017 - Bone Therapeutics: The preliminary documents for the Annual General Shareholder Meeting on 26 May 2017 have been made available
25/04/2017 - Bone Therapeutics announces the publication of its Annual Report 2016
mars
16/03/2017 - Bone Therapeutics Reports Full Year 2016 Results
10/03/2017 - Bone Therapeutics to participate in upcoming key investor conferences
09/03/2017 - Bone Therapeutics completes recruitment of 16 patients in ALLOB Phase I/IIA delayed-union study
06/03/2017 - Bone Therapeutics Strengthens Clinical Development Leadership with Appointment of Dr. Miguel Forte as Chief Medical Officer
03/03/2017 - Bone Therapeutics Notice of Full Year 2016 Results
janvier
20/01/2017 - Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2017
17/01/2017 - Bone Therapeutics Provides Business Update for Q4 2016
06/01/2017 - Bone Therapeutics Granted EUR 2.3 Million in Non-Dilutive Funding by the Walloon Region
décembre
21/12/2016 - Bone Therapeutics announces its financial calendar for 2017
novembre
08/11/2016 - Bone Therapeutics Business Update for Third Quarter 2016
02/11/2016 - Bone Therapeutics Notice of Q3 2016 Results - Results to be announced on 8 November 2016
octobre
11/10/2016 - Enrico Bastianelli to stand down as CEO of Bone Therapeutics
11/10/2016 - Transparency notification received from Theodorus II SA
05/10/2016 - Bone Therapeutics reports positive efficacy data for the ALLOB® Phase IIA spinal fusion trial
septembre
15/09/2016 - Bone Therapeutics receives positive ruling on Belgian Patent Income Deduction
août
30/08/2016 - Bone Therapeutics announces H1 results for 2016
25/08/2016 - Bone Therapeutics Half Year 2016 Results to be announced on 30 August 2016
juin
08/06/2016 - Bone Therapeutics demonstrates superiority of PREOB® in Phase IIB osteonecrosis study presented at EULAR
03/06/2016 - Bone Therapeutics celebrates ten years of innovation in bone cell therapy
mai
19/05/2016 - Bone Therapeutics to enhance value of its severe osteoporosis program by transitioning to allogeneic development
17/05/2016 - Bone Therapeutics announces further positive efficacy in ALLOB® Phase I/IIA delayed-union fracture trial
10/05/2016 - Bone Therapeutics Provides Business Update for the First Quarter of 2016
03/05/2016 - Bone Therapeutics completes recruitment of its ALLOB®Phase IIA spinal fusion study
avril
26/04/2016 - The preliminary documents for the Annual General Shareholder Meeting on 26 May 2016 have been made available
14/04/2016 - Bone Therapeutics announces the publication of its Annual Report 2015
mars
29/03/2016 - Bone Therapeutics Reports Full Year 2015 Results
29/03/2016 - Bone Therapeutics reports initial efficacy results from its PREOB® Phase IIA trial in severe osteoporosis
16/03/2016 - Bone Therapeutics Notice of Full Year 2015 Results: Results to be announced on 29 March 2016
février
24/02/2016 - Bone Therapeutics presents ALLOB® pre-clinical and early clinical efficacy data in spinal fusion at the Clinical Applications of Stem Cells Conference
17/02/2016 - Bone Therapeutics Provides Business Update for the Fourth Quarter of 2015
17/02/2016 - Bone Therapeutics treats 12 patients without safety concerns in ALLOB® Phase IIA spinal fusion trial
02/02/2016 - Bone Therapeutics extends Kasios collaboration
janvier
20/01/2016 - Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2016
18/01/2016 - Bone Therapeutics expands its delayed-union program with ALLOB® into multiple fractures
13/01/2016 - Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2016
05/01/2016 - Bone Therapeutics Granted an Additional EUR 2 Million in Non-Dilutive Funding by the Walloon Region
décembre
23/12/2015 - Bone Therapeutics announces its financial calendar for 2016
15/12/2015 - Bone Therapeutics completes recruitment of the first half of patients in ALLOB® Phase IIA spinal fusion trial
11/12/2015 - ALLOB® Delayed-Union Program Awarded at Cells Orthopedics Conference
novembre
30/11/2015 - Bone Therapeutics Awarded EUR 3 million in Funding to Support New Research Projects
18/11/2015 - Bone Therapeutics Provides Business Update for the Third Quarter of 2015
12/11/2015 - Bone Therapeutics’ ALLOB® receives Orphan Drug Designation for Osteogenesis Imperfecta from the EMA and FDA
09/11/2015 - Bone Therapeutics Appoints Thomas Lienard as Chief Business Officer
octobre
22/10/2015 - Transparency notification received from S.R.I.W. SA & Sofipôle SA
13/10/2015 - Bone Therapeutics to participate in key investor conferences in Q4 2015
septembre
28/09/2015 - Bone Therapeutics treats first patients in pioneering trial for minimally invasive treatment of failed spinal fusion
22/09/2015 - Bone Therapeutics announces half-year results for 2015
21/09/2015 - Bone Therapeutics Notice of Half Year Results 2015
07/09/2015 - Bone Therapeutics treats second patient cohort in ALLOB® Phase I/IIA delayed-union fracture trial
juin
22/06/2015 - Bone Therapeutics reports first results of its Phase IIA trial for PREOB® in severe osteoporosis
mai
15/05/2015 - Bone Therapeutics Provides Business Update for the First Quarter 2015
avril
28/04/2015 - Bone Therapeutics Reports 2014 Financial and Operational Results
24/04/2015 - Bone Therapeutics officially opens its new headquarters in Gosselies
13/04/2015 - Bone Therapeutics Establishes US Subsidiary
mars
23/03/2015 - Bone Therapeutics treats first patients in ALLOB® Phase IIA spinal fusion trial
02/03/2015 - Bone Therapeutics accelerates its ALLOB® Phase I/IIA Delayed-Union trial
février
19/02/2015 - Information on the total number of voting rights and shares
18/02/2015 - Bone Therapeutics announces its financial calendar for 2015
17/02/2015 - Transparency notification received from S.R.I.W. & Sofipôle, Mr J. Reymann, SFPI SA and Theodorus II SA
16/02/2015 - Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2015
11/02/2015 - Full exercise of Over-allotment Option: Total proceeds from the Initial Public Offering increased to €37 million
04/02/2015 - Bone Therapeutics raises EUR32.2M in a 2.5x oversubscribed successful Initial Public Offering on Euronext Brussels and Euronext Paris
janvier
21/01/2015 - Bone Therapeutics Launches its Initial Public Offering on Euronext Brussels and Euronext Paris
19/01/2015 - Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB® Phase I/IIA Delayed-Union Trial
16/01/2015 - Bone Therapeutics Announces Intention to Launch an Initial Public Offering on Euronext Brussels and Euronext Paris
05/01/2015 - Bone Therapeutics Expands Product Portfolio with New Research into Innovative Combined Cell-Matrix Product
décembre
04/12/2014 - Bone Therapeutics Authorised to Enrol patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB®
novembre
17/11/2014 - Bone Therapeutics and Kasios to collaborate on novel product for the optimisation of spinal fusion procedures
octobre
Bone Therapeutics extends ALLOB® phase I/IIa trial to Germany
septembre
Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion
Bone Therapeutics supports pioneering research by backing projects vital to regenerative medicine research (EN)
juillet
Bone Therapeutics and Partners awarded over €0.5 million M-ERA.net research funding to develop 3-D patient-tailored bone tissue engineered products
juin
Bone Therapeutics Starts Patient Treatment in First Ever Clinical Trial with Allogeneic Bone Cell Therapy Product
janvier
Bone Therapeutics to present at Biotech Showcase in San Francisco on Tuesday 14 January, 2014 at 10.15am
décembre
Bone Therapeutics and partners awarded highly competitive €3.8 million Marie Curie research grant
novembre
Bone Therapeutics’ pivotal phase III osteonecrosis trial with PREOB® hits a new milestone - 30 centres across Europe now active
Bone Therapeutics treats first patients in PREOB® pivotal phase IIb/III trial for the treatment of non-union fractures
octobre
Bone Therapeutics receives clearance for ALLOB® phase I/IIa trial
septembre
Bone Therapeutics Appoints Wim Goemaere as Chief Financial Officer
juin
Establishment of the Walloon Cell Therapy Platform: The platform aims to produce cell therapy medicines on a large scale
Fondation de la Plateforme Wallonne de Thérapie Cellulaire: La plateforme vise à produire les médicaments de thérapie cellulaire à grande échelle
avril
Bone Therapeutics and Erasme University Start Phase IIa Trial in Osteoporosis with its Cell Therapy Product PREOB®
Bone Therapeutics to Present at Upcoming Investor Conferences
mars
Bone Therapeutics Awarded Manufacturing Authorisation and European Approval to Produce Allogeneic Bone Cell Therapy Products
février
Bone Therapeutics Invests in Cell Therapy Manufacturing Facility
janvier
Bone Therapeutics Raises €7.7 Million in Series D Fundraising
octobre
Bone Therapeutics receives clearance for its pivotal phase III osteonecrosis trial with PREOB® in Europe and treats the first patients in the study
Bone Therapeutics reçoit l'approbation des autorités et traite les premiers patients dans son étude clinique de phase III en ostéonécrose avec son produit PREOB®
février
Bone Therapeutics lève 9,5M €
juin
Bone Therapeutics entre dans une nouvelle Phase de son développement Industriel